Microcap Ledger Scilex Holding Co $SCLX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Palo Alto, CA
- Fiscal year end
- December 31
- Shares outstanding
- 8,493,000 [10-Q 2026-08-14]
What the company doesAI summary of filing
Scilex Holding Company is a revenue-generating biopharmaceutical company that develops and commercializes non-opioid pain management products. The company markets three FDA-approved commercial products: ZTlido (lidocaine topical system) for postherpetic neuralgia pain, ELYXYB (celecoxib oral solution) for acute migraine treatment, and GLOPERBA (colchicine oral solution) for gout prophylaxis. The company also develops three clinical-stage product candidates: SP-102 (SEMDEXA, a corticosteroid gel for epidural injection in sciatica treatment, currently in Phase 3), SP-103 (a triple-strength lidocaine topical system for acute pain, Phase 2 complete), and SP-104 (low-dose naltrexone for fibromyalgia, Phase 1 complete). Additionally, the company has adopted a cryptocurrency treasury strategy to invest in bitcoin, Ethereum, and other blockchain-linked cryptocurrencies as a long-term holding. [10-K 2026-04-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $16.25M | −$160.64M | −$7.84M | $566.0K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $30.25M | −$374.05M | $3.82M | $4.96M | [10-K 2026-04-10] |
| FY ended Dec 2024 | $56.59M | −$72.81M | $19.35M | $3.27M | [10-K 2026-04-10] |
- Quarterly cash burn
- −$3.92M
- Cash runway Estimate
- ~0.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-01-14 | 243,312,885 | [10-Q 2025-01-17] |
| 2025-03-25 | 243,312,885 | [10-K/A 2025-04-29] |
| 2025-05-09 | 6,951,622 | [10-Q 2025-05-14] |
| 2025-08-08 | 6,955,697 | [10-Q 2025-08-13] |
| 2025-11-10 | 7,585,446 | [10-Q 2025-11-14] |
| 2026-04-03 | 8,491,267 | [10-K 2026-04-10] |
| 2026-05-15 | 8,491,267 | [10-Q 2026-05-20] |
| 2026-08-10 | 8,493,000 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-06-02; declared effective 2026-06-11 [S-3 2026-06-02]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-11-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-11-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-22] |
| 2024-11-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-20 | Scilex Holding Co | other | 50,000,000 | $0.32 | [4 2026-08-24] |
| 2026-07-03 | Sclx Stock Acquisition Jv Llc | other | 500,000 | — | [4 2026-07-07] |
| 2026-06-15 | Scilex Holding Co | other | 7,034,737 | — | [4 2026-06-26] |
| 2026-01-14 | Scilex Holding Co | sell | 5,115,586 | $0.72 | [4 2026-01-14] |
| 2026-01-13 | Scilex Holding Co | sell | 175,139 | $0.91 | [4 2026-01-14] |
| 2026-01-12 | Scilex Holding Co | sell | 10,674,816 | $0.88 | [4 2026-01-14] |
| 2026-01-08 | Scilex Holding Co | sell | 3,824,201 | $1.07 | [4 2026-01-08] |
| 2026-01-07 | Scilex Holding Co | sell | 4,835,581 | $1.20 | [4 2026-01-08] |
| 2026-01-06 | Scilex Holding Co | sell | 6,053,708 | $1.37 | [4 2026-01-08] |
| 2025-12-30 | Scilex Holding Co | sell | 9,657,300 | $0.54 | [4 2025-12-30] |
| 2025-12-29 | Scilex Holding Co | sell | 7,310,984 | $0.66 | [4 2025-12-30] |
| 2025-12-26 | Scilex Holding Co | sell | 3,689,016 | $0.75 | [4 2025-12-30] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Material agreement entered |
| 2026-08-24 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Material agreement entered |
| 2026-07-22 | 8-K | Material agreement entered; Acquisition or disposition completed |
| 2026-07-07 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-06 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-06-29 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-06-26 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-24 | 8-K | Shareholder vote results |
| 2026-06-02 | S-3 | Registration statement |
| 2026-05-20 | 10-Q | Quarterly report |
Alerts for $SCLX
Email me when Scilex Holding Co files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.